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Abstract 
Class 3 antiarrhythmic agents exhibit reverse rate-dependent lengthening of the action potential duration 
(APD), i.e. changes in APD are greater at longer than at shorter cycle lengths. In spite of the several 
theories developed to explain this reverse rate-dependency, its mechanism has been clarified only recently. 
The aim of the present study is to elucidate the mechanisms responsible for reverse rate-dependency in 
mammalian ventricular myocardium. Action potentials were recorded using conventional sharp 
microelectrodes from human, canine, rabbit, guinea pig, and rat ventricular myocardium in a rate-
dependent manner. Rate-dependent drug-effects of various origin were studied using agents known to 
lengthen or shorten action potentials allowing thus to determine the drug-induced changes in APD as a 
function of the cycle length. Both drug-induced lengthening and shortening of action potentials displayed 
reverse rate-dependency in human, canine, and guinea pig preparations, but not in rabbit and rat 
myocardium. Similar results were obtained when repolarization was modified by injection of inward or 
outward current pulses in isolated canine cardiomyocytes. In contrast to reverse rate-dependence, drug-
induced changes in APD well correlated with baseline APD values (i.e. that measured before the 
superfusion of drug or injection of current) in all of the preparations studied. Since the net membrane 
current (Inet), determined from the action potential waveform at the middle of the plateau, was inversely 
proportional to APD, and consequently to cycle length, it is concluded that that reverse rate-dependency 
may simply reflect the inverse relationship linking Inet to APD. In summary, reverse rate-dependency is an 
intrinsic property of drug action in the hearts of species showing positive APD - cycle length relationship, 
including humans. This implies that development of a pure K+ channel blocking agent without reverse rate-
dependent effects is not likely to be successful. 
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1. INTRODUCTION 
 
Dofetilide, d-sotalol, E-4031, ibutilide, and many UK compounds, which are selective blockers of the rapid 
delayed rectifier K+ current, are the most prominent representatives of class 3 antiarrhythmic agents. These 
drugs typically contain a methanesulfonamidophenyl structure within the molecule - in the case of 
dofetilide in two copies - (Fig. (1)) and display reverse rate-dependent effects. According to this mode of 
action a drug-induced lengthening of APD is greater at longer than at shorter cycle lengths [1, 2]. The 
reverse rate-dependent nature of the APD lengthening is undesirable because it minimizes drug effects on 
repolarization during tachyarrhythmias, while enhances their proarrhythmic potential at normal heart rates 
[1, 3, 4]. Therefore, development of class 3 drugs having direct rate-dependent properties when lengthening 
APD (i.e. lengthen APD better at shorter cycle lengths) was believed to be straightforward. 
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Fig. (1) Chemical structures of IKr blocker class 3 antiarrhythmic agents. Note the 
methanesulfonamidophenyl structure present in each compound (twice in dofetilide). 
 
Several hypotheses have been developed so far to explain the mechanism responsible for the reverse rate-
dependent APD modulation of class 3 antiarrhythmics. Based on results obtained in guinea pig ventricular 
myocytes, it was first suggested that significant accumulation of IKs may occur due to the incomplete 
deactivation of the current at fast heart rates, which would greatly attenuate the APD lengthening effect of 
IKr blockade [5]. This theory is strongly opposed by the finding that reverse rate-dependency was evident 
after full suppression of IKs [6]. 
Another hypothesis, the modulated receptor theory, was based on the rate-dependency of drug-channel 
interaction. Drug access to the channel and its binding and unbinding rates depend on the state of the 
channel [7, 8], which dynamically changes during the cardiac cycle. If the channel block developed 
preferentially during the diastole and dissipated during the action potential, reverse rate-dependent 
prolongation of APD would be expected. 
According to a third hypothesis the effect of IKr blockers is reduced, and consequently the drug-induced 
prolongation of APD becomes diminished, at fast heart rates due to the potassium accumulation in the 
sarcolemmal clefts. This theory was based on observations showing that IKr blockade by quinidine and 
dofetilide was attenuated when extracellular potassium concentration was elevated [9]. 
These latter two explanations had to be questioned after recognizing that many drugs that are known to 
lengthen APD independently of IKr blockade, like the Ito blocker 4-aminopyridine, the IKs inhibitor 
chromanol 293B and HMR 1556, the non-specific K+ channel blocker tetraethylammonium, the ICa 
activator BAY K 8644, or the INa activator veratridine, also exert reverse rate-dependent actions on APD. In 
other words, the phenomenon of reverse rate-dependency is not restricted to IKr blockade, but is observed 
with several drugs that lengthen APD independently of the underlying ionic mechanism. Due to the 
diversity of the chemical structures of agents in question (Fig. (2)), the modulated receptor theory is not 
likely to explain the phenomenon of reverse rate-dependency. 
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Fig. (2) Chemical structures of drugs known to lengthen APD either by blocking an outward current (IKs 
and Ito, but not IKr) or by activating an inward current (INa and ICa). 
 
Finally, rate-dependent changes in action potential morphology were also claimed to contribute to the 
reverse rate-dependency in guinea pig, canine, and human ventricular preparations by controlling the 
kinetic properties of IKr and IK1 during repolarization in a way potentially contributing to reverse rate-
dependency [10, 11]. 
All the above mentioned theories have been developed to explain the rate-dependent nature of APD 
prolongation. However, it has turned out that not only the lengthening, but also the drug-induced shortening 
of APD is reversely rate-dependent as it was shown with the INa blocker lidocaine, mexiletine, tetrodotoxin, 
as well as with the ICa blocker nifedipine, and the ATP-sensitive K+ channel opener nicorandil or 
lemakalim. Again, a group of agents with very diverse chemical structures were shown to display actions of 
reverse rate-dependent nature (Fig. (3)). 
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Fig. (3) Chemical structures of drugs known to shorten APD either by blocking INa (lidocaine, mexiletine, 
tetrodotoxin) and ICa (nifedipine), or by activating the ATP-sensitive K+ current (lemakalim and 
nicorandil). 
 
The multitude of theories developed so far to explain reverse rate-dependency indicates that its exact 
mechanism remained to be elucidated. In a recent study performed in dog myocardium APD modulation by 
drugs with diverse mechanisms was invariably characterized by reverse rate-dependency [12]. This was 
interpreted as reverse rate-dependence being a general intrinsic property of cardiac tissues, independently 
of the drug, tissue, or species studied, resulting from the shape of the relationship between the net 
membrane current (Inet) and APD [12, 13]. Such an interpretation was based on the assumption that APD 
modulation depends on drug-induced changes in Inet, independently of the specific current affected. This 
interpretation also predicts that, instead of depending on the heart rate (as suggested by the term reverse 
rate-dependency), the extent of drug-induced APD change may be a function of baseline APD, while the 
latter being a function of rate. Indeed, comparing reverse rate-dependency in various species it turned out 
that the magnitude of the drug-induced APD changes better correlated with baseline APD than with cycle 
length [14, 15]. 
In the present study we analyze all data regarding the rate-dependent properties of APD modulation by 
applying a variety of drugs that either enhance or block cardiac ion currents. Properties of ventricular 
myocardium of several mammalian species, including human, dog, rabbit, guinea pig and rat cardiac tissues 
are compared. Effects of transmembrane current injections were also studied as they were used to mimic 
the effects of ion channel blockers and activators in isolated cardiac cells. 
 
 4
1
Cycle length (s)
5321.50.3 0.5 0.7C
ha
ng
e 
of
 A
PD
90
(m
s)
150
250
350
AP
D
90
(m
s)
Cycle length (s)
1 5321.50.3 0.5 0.7
Cycle length (s)
1 321.50.3 0.5 0.7
AP
D
90
(m
s)
200
250
150 C
ha
ng
e 
of
 A
P
D
90
(m
s)
100
1
Cycle length (s)
321.50.3 0.5 0.7
-50
0
-75
-25
A
B
Nicorandil LidocaineControl
BaCl2Dofetilide VeratrineBAY K 8644Control 200450
C
DofetilideControl BaCl2 MexiletineSotalol E-4031 TTX
AP
D
90
(m
s)
300
500
700
100
Cycle length (s)
0.4 0.7 1 2 3 5
Cycle length (s)
0.4 0.7 1 2 3 5
0
100
200
300
-100C
ha
ng
e 
of
 A
PD
90
(m
s)D
0.3 0.5 0.7 1 2 31.5
0
100
200
300
AP
D
90
(m
s)
Cycle length (s)
Sotalol LemakalimControl
Cycle length (s)
C
ha
ng
e 
of
 A
P
D
90
(m
s)
-200
-100
0.3 0.5 1 2 31.5
0
100
0.7
Dog ventricle
Dog Purkinje
Guinea pig ventricle
Human ventricle
0
C
ha
ng
e 
of
 A
PD
90
(m
s)
AP
D
90
(m
s)
AP
D
90
(m
s)
C
ha
ng
e 
of
 A
P
D
90
(m
s)
AP
D
90
(m
s)
C
ha
ng
e 
of
 A
PD
90
(m
s)
AP
D
90
(m
s)
C
ha
ng
e 
of
 A
P
D
90
(m
s)
 
Fig. (4) Reverse rate-dependent actions of agents known to either lengthen (1 µM dofetilide, 1 µM E-4031, 
30 µM d-sotalol, 10 µM BaCl2, 1 µM BAY K 8644, 1 µg/ml veratrine) or shorten APD (15 µM lemakalim, 
100 µM nicorandil, 10 µM lidocaine, 10 µM mexiletine, 2 µM tetrodotoxin). Recordings were taken from 
multicellular preparations obtained from canine (A, B), guinea pig (C), and undiseased human (D) hearts 
using sharp microelectrodes. 
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2. REVERSE RATE-DEPENDENT NATURE OF APD MODIFICATION IN MAMMALIAN 
MYOCARDIUM 
 
Since the canine ventricular myocardium resembles most the human one regarding its electrophysiological 
properties [16-19], the frequency-dependent effects of various APD lengthening agents are demonstrated in 
canine multicellular ventricular preparations first. 
As shown in Fig. (4.A), the IKr blocker dofetilide [5], IK1 blocker BaCl2 [20], the ICa activator BAY K 8644 
[21], and the INa activator veratrine [22], display clearly reverse rate-dependent action on APD, i.e. the 
lengthening of APD increased monotonically with increasing the cycle length of stimulation, independently 
of the drug applied or the ion channel activated or blocked. This reversely rate-dependent prolongation of 
APD was equally observed if the change in APD was expressed in absolute values (in ms) or in a 
percentage form. These results clearly indicate that the reverse rate-dependent lengthening of APD is not 
restricted to IKr blockade, but is observed with any drug that is able to lengthen APD. 
In another preparation, in free running canine Purkinje strands, drugs known to shorten the cardiac action 
potentials were tested. Again, two agents having different targets to exert their shortening effects were 
applied. Lidocaine is known to suppress the window Na+ current [23], while nicorandil is a frequently used 
ATP-sensitive K+ channel opener [24]. As presented in Fig. (4.B), the effects of these agents on APD were 
not only similar in size, but their frequency-dependence was also almost identical: both drugs shortened 
APD stronger at longer than at shorter cycle lengths. In other words, not only the frequency-dependent 
lengthening of APD but also its shortening shows the properties of reverse rate-dependence. 
Basically similar results were obtained when a variety of APD lengthening and shortening agents were 
tested in other mammalian cardiac preparations including papillary muscles of the guinea pig and those 
derived from undiseased human hearts (Figs. (4.C) and (4.D)). All the agents applied to lengthen (the IKr 
blocker dofetilide, sotalol, and E-4031, the IK1 blocker BaCl2) or shorten (the INa blocker mexiletin and 
tetrodotoxin) APD shared the property of reverse rate-dependence. At this point one might conclude that 
the reverse rate-dependent nature of drug-action in the heart is a general property of mammalian cardiac 
tissues, independent of the species or preparation used, of the ion channel modified, or the direction of the 
resultant APD change. In the followings we examine that whether really is that the case? 
 
3. REVERSE RATE-DEPENDENT MODIFICATION OF APD DEPENDS ON THE LENGTH OF 
BASELINE APD 
 
The coincidence observed between human and canine ventricular tissues is not surprising, because the 
electrophysiological properties of human and canine myocardium are believed to be quite similar [16-19]. 
In contrast, the type and density of ion channels underlying the action potential in rabbit hearts are 
markedly different from those found in dog and human [25]. More importantly, APD displays a non-
monotonic dependency on cycle length in rabbits, maximum APD being achieved at an intermediate cycle 
length between 0.5 and 0.7 s as it is demonstrated in Fig. (5.A). This provides a unique opportunity to 
discriminate between rate-dependency and APD-dependency of drug-induced APD changes. In this case, 
sotalol [26] and lemakalim [27] were used to prolong and shorten APD, respectively. As expected, sotalol 
lengthened and lemakalim shortened APD in rabbit papillary muscles at all frequencies. However, in 
contrast to results obtained in canine, human, and guinea pig preparations, where the APD lengthening and 
shortening displayed monotonic reverse rate-dependency, the maximal drug-induced APD changes in 
rabbit preparations occurred at the intermediate cycle length between 0.5 and 0.7 s, at which the baseline 
APD was the longest (Fig. (5.A)). According to this result the magnitude of drug-effect seems to depend on 
the duration of the baseline action potential, rather than on the pacing rate, suggesting that longer action 
potentials are more sensitive to modulation than shorter ones, irrespective of the actual pacing rate. 
The above hypothesis can be best examined by studying the frequency-dependent properties of actions of 
various K+ and Ca2+ channel inhibitors on APD during the electrical restitution process of rat ventricular 
muscle. This preparation was chosen because (1) it has a set of ion currents markedly different from those 
of other species, and consequently, (2) its APD is shorter by one order of magnitude than that of the 
plateau-forming larger mammals [28-30], and most importantly, (3) its APD increases at higher heart rates 
- opposite to many other species [31, 32]. Therefore, the APD lengthening effect of the K+ channel blocker 
4-aminopyridine and tetraethylammonium, as well as the APD shortening effect of the Ca2+ channel 
blocker nifedipine and MnCl2 [33] was studied in rat as a function of the diastolic interval, a parameter 
indicating the proximity of the action potentials [34]. 
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Fig. (5.A) Frequency-dependent effects of 20 µM d-sotalol and 15 µM lemakalim on APD in rabbit 
papillary muscle preparations paced at various constant cycle lengths indicated in the abscissa. Note that 
these drug-induced APD changes failed to follow reverse rate-dependency. 
Fig. (5.B,C) Effects of 5 mM 4-aminopyridine, 5 mM tetraethylammonium, 2.5 µM nifedipine and 2 mM 
MnCl2 on the electrical restitution process of rat ventricular myocardium. Here APD was measured as a 
function of the diastolic interval. Drug effects were more pronounced at the shorter diastolic intervals. 
 
As could be expected from the negative APD – cycle length relationship in rat, all drug-induced APD 
changes were largely inversely proportional with the diastolic interval (Figs. (5.B) and (5.C)). This result is 
the opposite of that we have previously seen with canine, guinea pig, and human preparations, where the 
drug-induced changes were roughly directly related to cycle length. 
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Fig. (6) Drug-induced APD changes plotted as a function of the baseline (pre-drug) value of APD in canine 
(A), human (B), guinea pig (C), rabbit (D), and rat (E, F) multicellular ventricular preparations. 
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Fig. (7.A-C) Cycle length dependent changes in APD induced by inward (-30 pA) and outward (+60 pA) 
current pulses, injected throughout the action potential, in single canine ventricular cells. In panel (C) APD 
changes were plotted against control (0 pA) APD values measured at each cycle length. 
Fig. (7.D,E) Combined effects of BaCl2 and outward current injection on frequency-dependent APD 
changes. Representative superimposed action potentials recorded from a myocyte at 1 Hz in control, in the 
presence of 10 µM BaCl2, and in case of outward current injection in the presence of BaCl2 (D). The 
average APD values are plotted as a function of the pacing cycle length in panel (E). 
Fig. (7.F,G) Compensation of frequency-dependent APD changes using current injection. The APD 
shortening caused by increasing the pacing cycle length from 0.5 to 5 s in panel (F) was compensated by 
injection of inward current, while the lengthening of APD in response to the opposite frequency change 
could be compensated by an outward current pulse (G). 
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However, when these drug-induced APD changes were studied as a function of the baseline APD in rat, the 
larger drug effects were observed in cases of the longer baseline action potentials – similarly to results 
obtained in the other mammalian species. This indicates that dependency of APD on cycle length or 
diastolic interval and its modulation by drugs are tightly coupled, with cycle length and diastolic interval 
acting as the modulator of the baseline (pre-drug) APD and the latter directly determining the magnitude of 
drug-induced changes. This view is reinforced by Fig. (6), in which drug-induced APD changes are 
demonstrated to be proportional to the baseline (pre-drug) APD value in all the preparations studied so far 
(dog, human, guinea pig, rabbit, and rat) independently of the pacing cycle length or diastolic interval 
applied. 
 
4. REVERSE RATE-DEPENDENCY OF APD CHANGES IS INDEPENDENT OF THE WAY OF 
INDUCTION 
 
When studying the effect of an ion channel activator or blocker on action potential configuration, it can be 
considered as if we have added or removed an inward or outward current to/from the net membrane current 
flowing during the action potential plateau. This was tested in experiments performed in enzymatically 
isolated canine ventricular myocytes, impaled with sharp microelectrodes. In the experiments presented in 
Figs. (7.A-7.C) inward current pulses of -30 pA amplitude were injected into the myocytes in order to 
lengthen APD. Or alternatively, outward current pulses of +60 pA amplitude were injected in order to 
shorten action potentials. All these measurements were performed at various pacing cycle lengths changing 
gradually from 5 to 0.3 s. As shown in Figs. (7.A-7.C), the effect of a current injection on APD was 
reversely rate-dependent. Furthermore, the changes in APD induced by the inward and outward current 
pulses were linearly proportional to baseline APD values measured prior to current injection. Plots 
generated this way were almost indistinguishable from those obtained with an ion channel agonist or 
antagonist, indicating that the magnitude of APD modification is exclusively a function of the baseline 
APD, and independent of the nature of current change (electrical impulse or drug action), the gating 
kinetics and profiles of the ion current involved, or properties of the drug applied. This point is further 
demonstrated in Fig. (7.D), showing the effects of reversing the BaCl2-induced prolongation of APD by 
applying an injection of an outward current pulse. The BaCl2-induced prolongation of APD was completely 
offset at all cycle lengths by the concomitant injection of the same amount of current (Fig. (7.E)). APD 
prolongation by BaCl2 is the consequence of IK1 blockade. Since, neither IK1, nor its inhibition by BaCl2 are 
significantly rate-dependent, the resulting APD prolongation could be only influenced by the baseline value 
of APD, which, in turn, was determined by the pacing cycle length. In another series of such experiments, 
presented in Figs. (7.F) and (7.G), APD modifications induced by abrupt changes in the cycle length could 
be fully compensated by injections of current pulses having the appropriate amplitudes. 
 
5. MECHANISM OF REVERSE RATE-DEPENDENCY 
 
If the magnitude of an APD change of any kind of origin is in fact proportional to the baseline value of 
APD, it must somehow be related to the change in the net membrane current flowing during the action 
potential plateau. Inet was determined at half duration of the action potential from the slope of the middle 
portion of the plateau using the following simple equation: Inet = -Cm*dV/dt, where Cm is membrane 
capacitance and dV/dt is the momentary rate of membrane potential change (first time derivative). When 
Inet is expressed in pA/pF, its magnitude equals to the negative slope of the membrane potential change at 
any point during the action potential. The assumption that APD modulation reflects a change in Inet, 
independently of the specific current affected, was verified by plotting Inet against baseline APD under a 
variety of experimental conditions: at various pacing cycle lengths, before and after applying ion channel 
blockers or activators, and in the presence or absence of inward or outward current pulses. Four examples 
to constancy of the Inet – APD relationship are provided in Fig. (8). In Fig. (8.A) the plotted APD-Inet data 
pairs were derived from healthy human papillary muscle preparations exposed to various drugs at various 
pacing frequencies. Here clearly shown that Inet was a non-linear function of APD, and the APD-Inet 
relationships obtained with different drugs closely overlapped. The plot in Fig. (8.B) demonstrates the 
APD-Inet relationship obtained before and after superfusion of canine myocytes with BaCl2, the effect of 
inward and outward current injections on APD-Inet relationship is depicted in Fig. (8.C), while the pure 
cycle length-dependence is presented in Fig. (8.D). Common in all plots that the APD-Inet relationship 
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followed a hyperbolic function, and this shape was preserved independently of the experimental conditions 
applied. 
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Fig. (8) Reciprocal relationship obtained between action potential duration (APD90) and the magnitude of 
net membrane current (Inet) under various experimental conditions. 
 
Based on the result above reverse rate-dependency of drug-effects is a pure consequence of the reverse 
rate-dependent behavior of APD itself, namely because APD is greater at longer than at shorter cycle 
lengths in the majority of larger mammals including canine and human ventricular myocardium. In line 
with this argumentation, drug effects are expected to be positively rate-dependent in a species responding 
with shortening of APD to reduced pacing rates. Indeed, such changes were observed with sotalol and 
levkromakalim in rabbit papillary muscles within the range of 0.7-3 s, where APD is decreasing with 
increasing cycle length, and in rat while studying the effects of Ca2+ and K+ channel blockers on the 
electrical restitution process. Thus the explanation for the reverse rate dependency is quite simple and 
mechanistic. Since Inet flowing during the plateau is smaller in the case of a longer than a shorter action 
potential, a given current added or blocked (either as a current pulse, or due to a pharmacological 
intervention) is expected to cause a larger relative displacement of Inet, and consequently, a greater change 
in APD in case of a longer initial action potential. Therefore, the reverse rate-dependent nature of drug-
action can be considered as a general intrinsic property of canine and human cardiac cells. 
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6. CONCLUSIONS AND IMPLICATIONS 
 
The main goal of this study was to show why a drug-induced lengthening or shortening of APD is more 
pronounced at longer than at shorter cycle length in the majority of mammalian cardiac preparations, 
independently of the type of the ion current blocked or enhanced. It was also shown that reverse rate-
dependency seems to be an intrinsic property of the membrane, based on the relation of APD to Inet, rather 
than the consequence of a specific drug-ion channel interaction [5, 9, 35], or peculiar kinetics of ion 
currents [10] - as have been previously proposed. Especially, because lidocaine [23, 36, 37], mexiletine 
[38], tetrodotoxin [39], and veratrine [40-42] were uniformly shown to display positive rate-dependent 
interactions with sodium channels (i.e. they exert stronger block or activation of INa at higher frequencies). 
In spite of this, their action on APD showed clearly reverse rate-dependent characteristics. 
Taken together, it appears that reverse rate-dependency - although initially seemed to be a common feature 
of all cardiac preparations - is restricted only to species showing a positive APD – cycle length relationship. 
In contrast, since the drug-induced changes in APD well correlated with baseline APD in all of the species 
studied regardless of the ion current modified or the agent used, one may conclude that reverse rate-
dependency may simply be a consequence of the inverse relationship existing between Inet and APD. This 
confirms the prediction that APD modulation by drugs is more pronounced under conditions when action 
potentials are ab ovo longer, while the pacing rate being just one of the factors controlling baseline APD. 
Although the view that the mathematical relationship between APD and Inet may actually cause reverse 
rate-dependent APD changes was fully confirmed by the present results, several observations indicate that 
additional mechanisms may also influence the frequency-dependence of APD changes. For instance, if one 
exclusive mechanism accounted for the reverse rate-dependence, we would expect the relationship between 
drug-induced APD changes and baseline APD to be identical in all cases. However, such a relationship was 
almost linear with some drugs, while non-linear with others. This implies that even the dependency of APD 
modulation on baseline APD may include components that cannot be explained by a single mechanism. 
Furthermore, the existence of an intrinsic dependency of APD modulation on baseline APD does not rule 
out the contribution of other genuinely rate-dependent mechanisms, such as drug-ion channel interactions 
[5, 9, 35], or rate-dependency of ion current kinetics [10, 43] to determine the magnitude of the rate-
dependent APD change. Indeed, the magnitude of reverse rate-dependency was different among the various 
drugs tested. 
Present results suggest that development of IKr blockers with suitable features may at best reduce reverse 
rate-dependency of APD modulation, because intrinsic reverse rate-dependency needs to be offset in the 
first place. Thus, prolongation of APD with direct rate-dependency, although clinically desirable as an 
antiarrhythmic intervention, may be difficult to attain with any of the selective IKr blocker compounds that 
are currently used as class 3 antiarrhthmics. A more promising approach might be to combine APD 
prolongation with interventions suitable to minimize its arrhythmogenic effect at slow heart rates. This can 
probably be achieved by blocking of plateau inward currents, such as ICa or window INa [44, 45]. This view 
is supported by the results obtained by either combination of two distinct molecules [46-48], or by applying 
single drugs having intrinsically combined modes of action [49]. The main conclusion of the present study 
is that further development of selective IKr blocker drugs as potential class 3 antiarrhytmic agents are not 
likely to be successful. 
 
 
LIST OF ABBREVIATIONS 
APD  action potential duration 
CL  cycle length 
DI  diastolic interval 
Inet  net membrane current 
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